Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.37 |
| ▸ | KDM1A | O60341 | 10/20 | 0.36 |
| ▸ | HTR2B | P41595 | 6/20 | 0.34 |
| ▸ | HTR2A | P28223 | 5/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968179 | 0.87 | HTR2C (0.42) | HTR2CHTR2BHTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL967326 | 0.86 | HTR2C (0.41) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL2571507 | 0.78 | HTR2C (0.45) | HTR2CHTR2BHTR2AHTR6 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL1788708 | 0.69 | PNMT (0.66) | HTR2CKDM1A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29710285 | 0.69 | PNMT (0.66) | HTR2CKDM1A | |
| SCHEMBL970312 | 0.69 | NOTUM (0.34) | — | |
| SCHEMBL2406607 | 0.67 | HTR2B (0.36) | HTR2CHTR2BHTR2AHTR6 | |
| Trifluoroacetic Acid SCHEMBL5451230 | 0.67 | HTR2C (0.61) | HTR2CKDM1AHTR2BHTR2A | |
| Trifluoroacetic Acid SCHEMBL30343298 | 0.66 | CHRNB2 (0.56) | KDM1A | |
| Trifluoroacetic Acid SCHEMBL31006778 | 0.66 | HTR2C (0.44) | HTR2CKDM1AHTR2BHTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110002855-A1 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
| EP-2162451-A2 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | Neurogen Corporation (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009003003-A2 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002855-A1 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | HRH3, HRH4, HRH1 | HTR2C 90/4885KDM1A 1706/4885HTR2B 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.